Leerink analyst Joseph Schwartz upgraded Fulcrum Therapeutics (FULC) to Outperform from Market Perform with a price target of $12, up from $4, ahead of the 12mg sickle-cell disease data. The firm is intrigued by the results so far, thinks the HbF increase is likely to improve with longer/higher dosing, and believes the stock has more room to run, especially with growing scarcity value in the SCD space. Leerink sees a positively skewed risk/reward heading into the data, with an up/down of +100%/-40%.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FULC:
- Cisco upgraded, CoreWeave downgraded: Wall Street’s top analyst calls
- Cantor upgrades Fulcrum to Overweight on sickle cell opportunity
- Fulcrum Therapeutics upgraded to Overweight from Neutral at Cantor Fitzgerald
- Oppenheimer biotech analyst holds an analyst/industry conference call
- Cautious Outlook for Fulcrum Therapeutics Amid Phase 1b Progress and Enrollment Uncertainties